Description
Gunabrain
Description
Gunabrain based on N-acetylcysteine, selenium, manganese, coenzyme Q10, green tea and Indian ginseng (Withania somnifera), is a specific formulation in which the synergistic and complementary action of its components is designed to:
-protect brain functions to limit physiological cognitive decline;
-help memory, concentration and attention in cases of intense mental activity: intense study, work, intellectual overwork;
-help in the recovery of brain function, thanks to the improvement of arterial microcirculation;
-protect from oxidative damage, one of the causes of cell aging.
Ingredients
N-acetylcysteine; bulking agent: microcrystalline cellulose (cellulose gel); green tea (Camellia sinensis L. Kuntze) leaves extract 98% polyphenols (40% Epigallocatechin gallate), Withania (Withania somnifera L. Dunal) root and leaves extract; bulking agent: calcium phosphates; anti-caking agent: cross-linked sodium carboxymethylcellulose; coenzyme Q10; anti-caking agent: vegetable stearic acid; coating agent: hydroxypropylmethylcellulose; manganese carbonate, selenomethionine; stabilizer: polyvinylpolypyrrolidone; anti-caking agent: silicon dioxide; colorants: titanium dioxide, copper complexes of chlorophyllins.
Nutritional characteristics
*NRV: Nutrient Reference Values.
How to use
It is recommended to take 1 tablet per day. The tablets should be taken with a little water, preferably on an empty stomach.
Warnings
Keep out of reach of children under 3 years of age. Supplements are not intended as a substitute for a varied and balanced diet and a healthy lifestyle. Do not administer the product to children under 3 years of age.
Conservation
Store the product in a cool, dry place, away from light. The expiry date refers to the product correctly stored, in an intact package. Do not exceed the recommended daily dose.
Format
Pack of 30 tablets of 840 mg.
Net weight: 25.2 g.
Bibliography
1. Moreira PI, Harris PL et al. - Lipoic acid and n-acetyl cysteine decrease mitochondrial-related oxidative stress in alzheimer disease patient fibroblasts. J alzheimers Dis.; 2007. sep;12 (2): 195-206.
2. Tabner BJ et al. - Formation of hydrogen peroxide and hydroxyl radicals from a (beta) and alpha-synuclein as a possible mechanism of cell death in alzheimer's disease and parkinson's disease. free radic Biol med.; 2002. Jun 1;32(11):1076-83.
3. Adair JC et al. - Controlled trial of n-acetylcysteine for patients with probable alzheimer's disease. neurology; 2001. Oct 23;57(8): 1515-7.
4. Kidd PM - Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. alternate med rev.; 2008. Jun;13(2): 85-115.
5. Rizvi SI, Maurya PK - L-cysteine influx in erythrocytes as a function of human age. rejuvenation resi.; 2008. Jun;11(3): 661-5.
6. Savarino L. et al. - Serum concentrations of zinc and selenium in elderly people: results in healthy nonagenarians/centenarians. exp gerontol.; 2001. Feb;36(2): 327-39.
7. Kirschmann GJ, Kirschmann JD - Nutrition Almanac. Fourth edition, alfa omega editrice, rome; 1999.
8. Shults CW et al. - Effects of coenzyme Q10 in early parkinson's disease: evidence of slowing of the functional decline. neurological arch.; 2002. oct;59(10):1541-50.
9. Kuboyama T. et al. - Neuritic regeneration and synaptic reconstruction induced by withanolide a. Br J pharmacol.; 2005. Apr; 144(7):961-71.
10 . Parihar MS et al. - Susceptibility of hippocampus and cerebral cortex to oxidative damage in streptozotocin treated mice: prevention by extracts on Withania somnifera and aloe vera. J clin neurosci.; 2004. may;11(4):397-402.
11. Kuboyama t. et al. - Withanoside IV and its active metabolite, sominone, attenuate abeta(25-35) - induced neurodegeneration. eur J neurosci.; 2006. Mar;23(6):1417-26.
12. Bhattacharya SK et al. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. phytomedicines; 2000. Dec;7(6): 463-9.
13. Bhattacharya A. et al. - Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J ethnopharmacol.; 2001. Jan;74 (1):1-6.
14. Choudhary MI et al. - Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem Biophys res commun.; 2005. Aug 19;334(1):276-87.
15. Campanini E. - Dictionary of phytotherapy and medicinal plants. 2nd ed., ed. tecniche nuove, milan; 2004.
16. Du LL, Fu QY, Xiang LP, Zheng XQ, Lu JL, Ye JH, Li QS, et al. Tea Polysaccharides and Their Bioactivities. Molecules. 2016;21(11).
17. Yang CS, Wang H, Sheridan ZP. Studies on prevention of obesity, metabolic syndrome, diabetes, cardiovascular diseases and cancer by tea.J Food Drug Anal. 2018;26(1):1-13.
18. Chaudhary G, Sharma U, Jagannathan NR, Gupta YK. Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol. 2003;30(5-6):399-404.
19. Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Coenzyme Q10 Supplementation in Aging and Disease. Front Physiol. 2018;9:44.
Gunabrain based on N-acetylcysteine, selenium, manganese, coenzyme Q10, green tea and Indian ginseng (Withania somnifera), is a specific formulation in which the synergistic and complementary action of its components is designed to:
-protect brain functions to limit physiological cognitive decline;
-help memory, concentration and attention in cases of intense mental activity: intense study, work, intellectual overwork;
-help in the recovery of brain function, thanks to the improvement of arterial microcirculation;
-protect from oxidative damage, one of the causes of cell aging.
Ingredients
N-acetylcysteine; bulking agent: microcrystalline cellulose (cellulose gel); green tea (Camellia sinensis L. Kuntze) leaves extract 98% polyphenols (40% Epigallocatechin gallate), Withania (Withania somnifera L. Dunal) root and leaves extract; bulking agent: calcium phosphates; anti-caking agent: cross-linked sodium carboxymethylcellulose; coenzyme Q10; anti-caking agent: vegetable stearic acid; coating agent: hydroxypropylmethylcellulose; manganese carbonate, selenomethionine; stabilizer: polyvinylpolypyrrolidone; anti-caking agent: silicon dioxide; colorants: titanium dioxide, copper complexes of chlorophyllins.
Nutritional characteristics
| Average values | per 100 g | per tablet |
| Energy | 1.157 kJ 277 kcal |
10 kJ 2 kcal |
| Fats of which saturated fatty acids |
2.81 g 2.23 g |
0.024 g 0.019 g |
| Carbohydrates of which sugars |
28.97 g 0.54 g |
0.243 g 0.005 g |
| Proteins | 18.55 g | 0.156 g |
| Salt | 0.58 g | 0.005 g |
| Coenzyme Q10 | 2.381 mg | 20 mg |
| Manganese | 595.2 mg | 5 mg (250% NRV*) |
| Selenium | 5,952.4 mcg | 50 mcg (91% NRV*) |
| N-acetylcysteine | 29.8 g | 250 mg |
| Green tea is | 11.9 g | 100 mg |
| Withania somnifera is | 11.9 g | 100 mg |
How to use
It is recommended to take 1 tablet per day. The tablets should be taken with a little water, preferably on an empty stomach.
Warnings
Keep out of reach of children under 3 years of age. Supplements are not intended as a substitute for a varied and balanced diet and a healthy lifestyle. Do not administer the product to children under 3 years of age.
Conservation
Store the product in a cool, dry place, away from light. The expiry date refers to the product correctly stored, in an intact package. Do not exceed the recommended daily dose.
Format
Pack of 30 tablets of 840 mg.
Net weight: 25.2 g.
Bibliography
1. Moreira PI, Harris PL et al. - Lipoic acid and n-acetyl cysteine decrease mitochondrial-related oxidative stress in alzheimer disease patient fibroblasts. J alzheimers Dis.; 2007. sep;12 (2): 195-206.
2. Tabner BJ et al. - Formation of hydrogen peroxide and hydroxyl radicals from a (beta) and alpha-synuclein as a possible mechanism of cell death in alzheimer's disease and parkinson's disease. free radic Biol med.; 2002. Jun 1;32(11):1076-83.
3. Adair JC et al. - Controlled trial of n-acetylcysteine for patients with probable alzheimer's disease. neurology; 2001. Oct 23;57(8): 1515-7.
4. Kidd PM - Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. alternate med rev.; 2008. Jun;13(2): 85-115.
5. Rizvi SI, Maurya PK - L-cysteine influx in erythrocytes as a function of human age. rejuvenation resi.; 2008. Jun;11(3): 661-5.
6. Savarino L. et al. - Serum concentrations of zinc and selenium in elderly people: results in healthy nonagenarians/centenarians. exp gerontol.; 2001. Feb;36(2): 327-39.
7. Kirschmann GJ, Kirschmann JD - Nutrition Almanac. Fourth edition, alfa omega editrice, rome; 1999.
8. Shults CW et al. - Effects of coenzyme Q10 in early parkinson's disease: evidence of slowing of the functional decline. neurological arch.; 2002. oct;59(10):1541-50.
9. Kuboyama T. et al. - Neuritic regeneration and synaptic reconstruction induced by withanolide a. Br J pharmacol.; 2005. Apr; 144(7):961-71.
10 . Parihar MS et al. - Susceptibility of hippocampus and cerebral cortex to oxidative damage in streptozotocin treated mice: prevention by extracts on Withania somnifera and aloe vera. J clin neurosci.; 2004. may;11(4):397-402.
11. Kuboyama t. et al. - Withanoside IV and its active metabolite, sominone, attenuate abeta(25-35) - induced neurodegeneration. eur J neurosci.; 2006. Mar;23(6):1417-26.
12. Bhattacharya SK et al. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. phytomedicines; 2000. Dec;7(6): 463-9.
13. Bhattacharya A. et al. - Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J ethnopharmacol.; 2001. Jan;74 (1):1-6.
14. Choudhary MI et al. - Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem Biophys res commun.; 2005. Aug 19;334(1):276-87.
15. Campanini E. - Dictionary of phytotherapy and medicinal plants. 2nd ed., ed. tecniche nuove, milan; 2004.
16. Du LL, Fu QY, Xiang LP, Zheng XQ, Lu JL, Ye JH, Li QS, et al. Tea Polysaccharides and Their Bioactivities. Molecules. 2016;21(11).
17. Yang CS, Wang H, Sheridan ZP. Studies on prevention of obesity, metabolic syndrome, diabetes, cardiovascular diseases and cancer by tea.J Food Drug Anal. 2018;26(1):1-13.
18. Chaudhary G, Sharma U, Jagannathan NR, Gupta YK. Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol. 2003;30(5-6):399-404.
19. Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Coenzyme Q10 Supplementation in Aging and Disease. Front Physiol. 2018;9:44.
